Afinion sales gather momentum, but marketing costs hit Axis-Shield profits
This article was originally published in Clinica
Anglo-Norwegian diagnostics company Axis-Shield saw a drop in pre-tax profits for the first half of 2007, as the cost of scaling up the production of, and commercialising, its new-generation Afinion analyser upped operating expenses, and unfavourable foreign exchange rates weighed down on revenues.
You may also be interested in...
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.